Focus: Relmada Therapeutics is a public biotech company focused on small-molecule therapeutics for pain, oncology, and neurology, with a pipeline anchored by REL-1017 for major depressive disorder and NDV-01 for bladder cancer. The company operates with a lean structure of 5,000+ employees and maintains active clinical programs across multiple indications.
Profile data last refreshed 12h ago · AI intelligence enriched 2mo ago
No open roles listed right now. Follow Relmada Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Relmada Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Relmada Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Relmada: 'Hold' Based On Needed NVD-01 Manufacturing Push For IND YE2026 And Sepranolone Advancement - Seeking Alpha
Relmada: 'Hold' Based On Needed NVD-01 Manufacturing Push For IND YE2026 And Sepranolone Advancement Seeking Alpha
Relmada Therapeutics (RLMD) CFO buys 200,000 shares in open market - Stock Titan
Relmada Therapeutics (RLMD) CFO buys 200,000 shares in open market Stock Titan
Relmada Therapeutics Announces Urology Chief Medical Officer Exit - TipRanks
Relmada Therapeutics Announces Urology Chief Medical Officer Exit TipRanks
Senior managers will hold one-on-one meetings in Boston at a Wells Fargo healthcare conference Sept. 8-10. - Stock Titan
Senior managers will hold one-on-one meetings in Boston at a Wells Fargo healthcare conference Sept. 8-10. Stock Titan
Relmada Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference - GlobeNewswire
Relmada Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference GlobeNewswire
Relmada Therapeutics (RLMD) Slides 4.2% to $4.33 as Clinical-Stage Pressures Weigh - Advance Decline Line - vinanet.vn
Relmada Therapeutics (RLMD) Slides 4.2% to $4.33 as Clinical-Stage Pressures Weigh - Advance Decline Line vinanet.vn
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Recent peer-reviewed publications with author affiliations at this company
New Synthesis and Pharmacological Evaluation of Enantiomerically Pure (R)- and (S)-Methadone Metabolites as N-Methyl-d-aspartate Receptor Antagonists.
Long-Term Safety and Efficacy of Esmethadone in Patients With Major Depressive Disorder: Findings From a 12-Month Open-Label Study.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo